Triple Negative Breast Cancer Metastatic
Oncology·MeSH: Triple Negative Breast Neoplasms
Prevalence
287.0 / 100K
Incidence
128.0 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| QL1706 | Valneva SE (VALN) |
Frequently asked questions
How many drugs are in development for Triple Negative Breast Cancer Metastatic?
BioSniper tracks 1 drug in development for Triple Negative Breast Cancer Metastatic across 1 company.
How many clinical trials target Triple Negative Breast Cancer Metastatic?
There are 1 clinical trial targeting Triple Negative Breast Cancer Metastatic tracked by BioSniper.
What is the prevalence of Triple Negative Breast Cancer Metastatic?
The estimated prevalence of Triple Negative Breast Cancer Metastatic is approximately 287.0 per 100,000 population.
Deep-dive into Triple Negative Breast Cancer Metastatic
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis